Evaxion Reports Durable Three-Year Responses With EVX-01 In Advanced Melanoma
Evaxion A/S reported that patients in a Phase 2 study of its personalized cancer vaccine EVX-01 for advanced melanoma maintained responses for three years, with no tumor progression. The company will present the data at ESMO 2026, showing a 75% response rate and 92% clinical benefit at two years. EVX-01 is currently in development for advanced solid tumors. EVAX stock closed at $2.83 on October 16, 2026, and is up 2.83% in pre-market trading.
How this was made
The 30-second read
Why it matters
The three‑year data reinforce the vaccine's durability, potentially driving the stock higher ahead of the ESMO presentation.
Market read
First report of extended efficacy data for a micro‑cap biotech, likely to move EVAX shares.
What to watch
Future regulatory approval path and reimbursement landscape remain uncertain.
Background
Evaxion A/S (EVAX) is a Danish biotech developing personalized cancer vaccines using an AI‑Immunology platform.
Ticker impact
Evaxion disclosed three-year Phase 2 data showing durable responses and no tumor progression in advanced melanoma patients.
upward pressure as market prices in the durable response data
First disclosure of 3‑year outcomes, a material clinical milestone for a biotech micro‑cap.
Market effects
Strengthens confidence in personalized cancer vaccine platforms, may boost peer biotech sentiment.
European biotech sector sees positive catalyst from Danish firm.
Adds to broader interest in AI‑driven immunotherapy approaches.
Counterpoint
Small sample size and early‑stage trial may limit long‑term commercial impact.
Key entities
- companyEvaxion A/S
Developer of the EVX-01 personalized cancer vaccine.
- companyMerck
Provider of KEYTRUDA, combined with EVX-01 in earlier trial phases.
